What the FDA labels say about taking them together
Insulin degludec and pentoxifylline
Insulin degludec's FDA label of July 1, 2022 names pentoxifylline in its drug interactions section; the pentoxifylline label PlainMeds reads does not name insulin degludec. The insulin degludec label: “… agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 …”
Check it at the source: the insulin degludec FDA label on DailyMed (effective July 1, 2022, Novo Nordisk Pharma, Inc.); the pentoxifylline FDA label on DailyMed (effective May 15, 2026, Rising Pharma Holdings, Inc.).
What does the insulin degludec label say about pentoxifylline?
Insulin degludec label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs.
Source: FDA drug label (Insulin Degludec), Novo Nordisk Pharma, Inc., effective July 1, 2022 (SPL set c1be283d-4b1d-4996-b2a7-4488dbff3037), via openFDA; the full label on DailyMed
What does the pentoxifylline label say about insulin degludec?
Pentoxifylline's label (effective May 15, 2026) does not name insulin degludec in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pentoxifylline), Rising Pharma Holdings, Inc., effective May 15, 2026 (SPL set cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin degludec | Pentoxifylline | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $11.39 per mL 100 unit/mL pen | $0.227 per tablet 400 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once